Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases.

Autor:	Berges, Nina1, Hehmann-Titt, Grit2, Hristodorov, Dmitrij1, Melmer, Georg2, Thepen, Theo3 thepen@ime.fraunhofer.de, Barth, Stefan1,3 barth@hia.rwth-aachen.de
Zdroj:	Antibodies (2073-4468). Mar2014, Vol. 3 Issue 1, p92-115. 24p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu